Table 1. Baseline characteristics.
| Patients | N= 48 pts | ||
|---|---|---|---|
| Sex (male) | 34 (71%) | ||
|
| |||
| Age (median) | 56 yrs (34-71) | ||
|
| |||
| Stage | |||
| I and II | 5 | ||
| III and IV | 43 | ||
|
| |||
| Median no of regimens prior to SCT | 1(1-5) | ||
| 1 | 30 | ||
| 2 or more | 18 | ||
|
| |||
| Regimens | |||
| R-CHOP | 30 (median age:58 <40-71>) | ||
| R-Hyper-CVAD/Ara-c/MTX | 9 (median age: 54<48-65>) | ||
| R-bortezomib-CVAD | 9 (median age: 57 <34-63>) | ||
|
| |||
| Number of patients in CR prior to SCT | 37 | ||
|
| |||
| Type of Transplantation | |||
| Auto- SCT | 40 (33 in CR /8 in PR) | ||
| Allo-SCT | 8 (4 in CR/3 in PR) | ||
| RIC/MRD | 2 | ||
| RIC/MUD | 5 | ||
| Myeloablative/MRD | 1 | ||
|
| |||
| PS | 0-1 | ||
| Median ratio of LDH: upper limit of normal | 0.73 (range: 0.54- 2.44) | ||
| Median WBC count at diagnosis (109/l) | 6.8 (1.8- 22.9) | ||
|
| |||
| MIPI score (Type of transplant) | Auto | Allo | |
| Low | 22 | 3 | |
| Intermediate | 12 | 1 | |
| High | 2 | 1 | |
| N/A (n=7) | |||
|
| |||
| MIPI score (Regimen used) | R-CHOP | R-Hyper-CVAD | R-Bortezomib-CVAD |
| Low | 11 | 7 | 7 |
| Intermediate | 9 | 1 | 1 |
| High | 5 | ||
|
| |||
| Conditioning Regimen | |||
| CBV | 40 | ||
| Flu/Bu | 5 | ||
| FCR | 1 | ||
| TBI based | 2 | ||
SCT: Stem cell transplantation; R-CHOP: Rituximab, Cyclophosphamide, Adriamycin, Vincristine, prednisone; R-Hyper-CVAD/Ara-C/MTX: Hyper fractionated cyclophosphamide, vincristine, Adriamycin, Dexamethasone, Cytarabine and methotrexate; CR: complete remission, Auto-SCT: autologous ; Allo-SCT: allogeneic stem cell transplantation, RIC: reduced intensity conditioning, MRD- Matched related donor MUD: matched unrelated donor, PS: performance status, LDH: lactate dehydrogenase, WBC: white blood cells, MIPI: mantle cell lymphoma international prognostic index; CBV: cyclophosphamide, BCNU and etoposide, Flu/Bu: Fludarabine/ Busulfan; FCR: Fludarabine, Cyclophosphamide and rituximab ; TBI: Total body Irradiation.
R-CHOP: Cyclophosphamide 750 mg/m2 iv day 1; Adriamycin 50 mg/m2 iv day 1; Vincristine 1.4 mg/m2 iv day 1 (capped at 2 mg); Prednisone 100 mg/day p.o. × 5 days; Rituximab 375 mg /m2 iv day 1 Cycles are given every 21 days.
R-Hyper-CVAD/Ara-c/MTX: Cycles 1,3, and 5: Cyclophosphamide 300 mg/m2 iv over 2 hours, every 12 hours, for 6 doses on days 1-3; Mesna 600 mg/m2 iv daily, day 1-3, starting 1 hour before cyclophosphamide and completed 12 hours after the last cyclophosphamide dose; Vincristine 2 mg iv day 4 and 11; Doxorubicin 50 mg/m2 iv over 2 hours on day 4; Dexamethasone 40 mg/day po days 1 to 4 and 11 to 14. Cycles 2, 4, and 6: Methotrexate 1 gm/m2 iv over 24 hours on day 1 loading dose 100 mg/m2 over 2 hours, then 900 mg/m2 over 23 hours; Ara-C 3 gm/m2 iv over 2 hours. Rituximab 375 mg/m2 with each cycle. Cycles are given at 21 day intervals if possible.
Bortezomib-R-CVAD: Cyclophosphamide 300 mg/m2 iv over 3 hours, every 12 hours, for 6 doses on days 1-3. Mesna 60mg/m2/dose iv, q4h × 18 during cytoxan; Vincristine 1mg iv day 3; Doxorubicin 25 mg/m2 iv continuous infusion, over 24 hours x2 day 1 and day 2; Rituximab 375 mg/m2 iv day 1; Dexamethasone 40 mg/day po days 1 to 4 bortezomib 1.3 mg/m2 iv day 1 and 4. Cycles are given every 21 days.